Professor of Experimental Cancer Medicine, King’s College London, and Consultant in Medical Oncology, Guy’s and St. Thomas’ Hospitals London. He holds a PhD in Cancer Biology from the Institute of Cancer Research in London, and a degree in biochemistry from the University of Oxford. Our Principle Investigator for our planned PoC trial.
Professor James Spicer
Professor of experimental cancer medicine (KCL) and consultant in medical oncology
Holger Karsunky is the Co-Founder in Residence of Deep Valley Labs. He previously worked at Stemcentrx as Director of Cancer Biology. Former Senior Director for abbVie Oncology. Former R&D Director for Cellerant Therapeutics, the only other company in the world to have successfully produced GMP grade neutrophil progenitors (through to PIII clinical trials for neutropenia).
Dr Holger Karsunky
Former Senior Director in Oncology for abbVie & Cellerant Therapeutics
Clinical Immunopathologist. Director of the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital and Professor of Cell & Tissue Therapy at UCL. He is a world-leader in the development of cell and tissue medicines for immunotherapy and transplantation and is an MHRA QP for release of Advanced Therapy Medicinal Products, for use in clinical trials. Founder of Achilles Therapeutics, Cell Medica, InMune Bio
Professor Mark Lowdell
Director of Cellular Therapy at The Royal Free & Founder of INmuneBio & Achilles Therapeutics
Prof. John Campbell completed his PhD in Pathology at Edinburgh in 1995, and has over 30 years’ experience developing cellular therapeutics in the academic, industrial and healthcare sectors.
Led manufacturing development of cellular therapeutics at Miltenyi Biotec. Specialises in transferring immune cell processes from lab to first-in-human clinical trials.
Professor John Campbell
Director Cell & Advanced Therapeutics SNBTS (NHS)
Clinician Scientist and Consultant Medical Oncologist at Imperial College, London. David leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies. Expert in translational oncology within the specific setting of early phase clinical trials.
Dr David Pinato
Medical Oncologist & Director of Developmental Cancer Therapeutics, Imperial College
Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity College Dublin (TCD). He is Academic Director of Trinity Biomedical Sciences Institute (TBSI) Co-founder of Opsona Therapeutics, TriMod Therapeutics and Parvalis Tx, biotech companies focused on developing immunotherapeutics for inflammatory diseases and cancer.